NASDAQ:VIVO - Meridian Bioscience Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $30.00
  • Forecasted Upside: 15.47 %
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$25.98
▲ +0.21 (0.81%)

This chart shows the closing price for VIVO by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Meridian Bioscience Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for VIVO and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for VIVO

Analyst Price Target is $30.00
▲ +15.47% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Meridian Bioscience in the last 3 months. The average price target is $30.00, with a high forecast of $0.00 and a low forecast of $0.00. The average price target represents a 15.47% upside from the last price of $25.98.

This chart shows the closing price for VIVO for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 1 polled investment analysts is to buy stock in Meridian Bioscience. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/29/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/27/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/28/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/26/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/24/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/22/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/23/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/23/2022

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/8/2022HC WainwrightReiterated RatingBuy$30.00Medium
2/7/2022HC WainwrightBoost Price TargetBuy$28.00 ➝ $30.00High
11/15/2021HC WainwrightBoost Price TargetBuy$27.00 ➝ $28.00Medium
10/8/2021HC WainwrightReiterated RatingBuy$27.00Low
8/9/2021HC WainwrightLower Price TargetBuy$30.00 ➝ $27.00Medium
7/26/2021HC WainwrightReiterated RatingBuy$30.00Medium
6/29/2021HC WainwrightReiterated RatingBuy$30.00High
5/10/2021HC WainwrightLower Price TargetBuy$32.00 ➝ $30.00High
2/24/2021HC WainwrightLower Price TargetBuy$34.00 ➝ $32.00High
2/8/2021HC WainwrightReiterated RatingBuy$30.00 ➝ $34.00Medium
2/8/2021Piper SandlerBoost Price TargetOverweight$26.00 ➝ $34.00Medium
1/19/2021HC WainwrightReiterated RatingBuy$30.00Low
11/16/2020Piper SandlerBoost Price TargetOverweight$24.00 ➝ $26.00Medium
11/16/2020HC WainwrightLower Price TargetBuy$34.00 ➝ $30.00High
9/18/2020HC WainwrightReiterated RatingBuy$34.00High
7/27/2020HC WainwrightInitiated CoverageBuy$34.00High
5/11/2020William BlairUpgradeMarket Perform ➝ OutperformLow
2/8/2020William BlairReiterated RatingMarket PerformMedium
5/1/2019Piper Jaffray CompaniesUpgradeUnderweight ➝ Neutral$15.00 ➝ $11.00High
4/3/2019Robert W. BairdLower Price TargetNeutral$17.00 ➝ $14.00High
4/2/2019Piper Jaffray CompaniesLower Price TargetUnderweight$17.00 ➝ $15.00High
(Data available from 5/24/2017 forward)

News Sentiment Rating

0.58 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/26/2021
  • 1 very positive mentions
  • 3 positive mentions
  • 4 negative mentions
  • 0 very negative mentions
11/25/2021
  • 2 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/25/2021
  • 1 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/24/2022
  • 5 very positive mentions
  • 13 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
2/23/2022
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/25/2022
  • 1 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
4/24/2022
  • 6 very positive mentions
  • 11 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
5/24/2022

Current Sentiment

  • 6 very positive mentions
  • 11 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Meridian Bioscience logo
Meridian Bioscience, Inc., a life science company, develops, manufactures, distributes, and sells diagnostic test kits primarily for gastrointestinal and respiratory infectious diseases, and elevated blood lead levels worldwide. The company operates through Diagnostics and Life Science segments. The Diagnostics segment offers testing platforms, including real-time PCR amplification under the Revogene brand; isothermal DNA amplification under the Alethia brand; lateral flow immunoassay using fluorescent chemistry under the Curian brand; rapid immunoassay under the ImmunoCard and ImmunoCard STAT! brands; enzyme-linked immunoassays under the PREMIER brand; anodic stripping voltammetry under the LeadCare brands; and urea breath testing for H. pylori under the BreathID and BreathTek brand. This segment also offers respiratory illness assays, such as tests Group A strep, mycoplasma pneumonia, influenza, and pertussis; and blood chemistry products for LeadCare test kits for the detection of lead in blood. It sells products through direct sales force and independent distributors to acute care hospitals, reference laboratories, outpatient clinics, and physician office laboratories. The Life Science segment offers bulk antigens, antibodies, PCR/qPCR reagents, nucleotides, and bioresearch reagents used by in vitro diagnostic manufacturers, as well as researchers in immunological and molecular tests for human, animal, plant, and environmental applications. Meridian Bioscience, Inc. was incorporated in 1976 and is headquartered in Cincinnati, Ohio.
Read More

Today's Range

Now: $25.98
Low: $25.65
High: $26.12

50 Day Range

MA: $26.13
Low: $23.75
High: $28.01

52 Week Range

Now: $25.98
Low: $17.00
High: $28.72

Volume

219,773 shs

Average Volume

441,328 shs

Market Capitalization

$1.13 billion

P/E Ratio

18.43

Dividend Yield

N/A

Beta

0.34

Frequently Asked Questions

What sell-side analysts currently cover shares of Meridian Bioscience?

The following sell-side analysts have issued reports on Meridian Bioscience in the last year: HC Wainwright, StockNews.com, and Zacks Investment Research.
View the latest analyst ratings for VIVO.

What is the current price target for Meridian Bioscience?

0 Wall Street analysts have set twelve-month price targets for Meridian Bioscience in the last year. Their average twelve-month price target is $30.00, suggesting a possible upside of 15.5%.
View the latest price targets for VIVO.

What is the current consensus analyst rating for Meridian Bioscience?

Meridian Bioscience currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe VIVO will outperform the market and that investors should add to their positions of Meridian Bioscience.
View the latest ratings for VIVO.

How do I contact Meridian Bioscience's investor relations team?

Meridian Bioscience's physical mailing address is 3471 RIVER HILLS DRIVE, CINCINNATI OH, 45244. The company's listed phone number is (513) 271-3700 and its investor relations email address is [email protected] The official website for Meridian Bioscience is www.meridianbioscience.com. Learn More about contacing Meridian Bioscience investor relations.